Kimpton faces hotel shake-up, loses most of its San Francisco hotels
 
Posted: 31 Jul 2015, 5:53 pm
San Francisco-based Kimpton Hotels and restaurants is undergoing a major shake-up ? it's lost the management contract for most of its San Francisco hotels, and some say it?s all because of its earlier acquisition by InterContinental Hotels Group. Kimpton will no longer manage the Hotel Palomar San Francisco, Hotel Monaco San Francisco, Harbor Court Hotel, Triton Hotel, Prescott Hotel, Tuscan Inn and the Argonaut hotel. That leaves only the Buchanan hotel in Japantown and the Sir Francis Drake?

Read the full article


Why ZenPayroll is hiring for more than 1,000 jobs — not in San Francisco
 
Posted: 31 Jul 2015, 5:36 pm
Zenpayroll is taking a lot of jobs to Denver. The company is opening a second office in the Mile High City, where it said it will hire 100 people right off the bat, and eventually reach 1,750 employees. The online payroll software company started the year with 50 employees, but now has closer to 240 in its San Francisco headquarters. Co-founder and CEO Joshua Reeves said the company could no longer contain its growing workforce in one city. ?I realized not everyone in the world needs to move?

Read the full article


Uber lands $1 billion, valuation soars to $51 billion
 
Posted: 31 Jul 2015, 4:04 pm
Uber on Friday became the second venture-backed company to hit a valuation of $50 billion and it did it a year faster than Facebook did. The Wall Street Journal cited unnamed sources who said the San Francisco on-demand transportation company raised $1 billion in new funding that values the company at about $51 billion. More on Uber Cover story: Why Uber's labor model is under threat Photos: What Uber's new S.F. headquarters in Mission Bay will look like Profile: CEO drives Uber past controversies?

Read the full article


Biotech startup Global Blood Therapeutics files for $124.2M IPO
 
Posted: 31 Jul 2015, 3:35 pm
Early-stage biotech startup Global Blood Therapeutics set a target range for its IPO, filing on Thursday with the Securities and Exchange Commission to raise up to $124.2 million to develop a small-molecule therapy for sickle cell disease. The company will offer six million shares at a target price range of $16 to $18. At the midpoint of the proposed range, the company would command a fully diluted market value of $528 million. The company plans to list on the Nasdaq under the symbol GBT. Morgan?

Read the full article




Complete News Archive



Thanks for viewing our new website!
Posted September 18, 2012